Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-α 2b and ribavirin

A. J. Buckton; R. Kulasegaram; S. L. Ngui; M. Fisher; R. James; S. Rangarajan; C. G. Teo

doi:10.1016/j.jcv.2007.05.010

Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-α 2b and ribavirin

A. J. Buckton^*, R. Kulasegaram, S. L. Ngui, M. Fisher, R. James, S. Rangarajan, C. G. Teo

^*Corresponding author for this work

Clinical Services Unit

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

An HIV-1/hepatitis C virus (HCV) co-infected patient with haemophilia received a 48-week course of pegylated interferon-α-2b and ribavirin therapy for genotype 5a HCV infection. Virological response was achieved at week 24. At the end of treatment, HCV RNA in serum was detected and identified to belong to genotype 2b, rather than genotype 5a. A sensitive method for identifying minority HCV genotypes in pre-treatment serum showed genotype 2b HCV carriage prior to treatment. Sequencing the interferon sensitivity-determining region of the HCV NS5A gene obtained from pre-, intra- and post-treatment sera revealed emergence of quasispecies bearing R → K and M → A/T mutations at codons 2222 and 2223, respectively. Occult presence of minority HCV subpopulations and their acquisition of mutations following therapy can result in poor treatment outcome.

Original language	English
Pages (from-to)	60-63
Number of pages	4
Journal	Journal of Clinical Virology
Volume	40
Issue number	1
DOIs	https://doi.org/10.1016/j.jcv.2007.05.010
Publication status	Published - Sept 2007

Bibliographical note

Funding Information:
The laboratory studies were funded by a grant from the Department of Health, England.

Keywords

Genotype switch
Haemophilia
Multitypic HCV infection

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jcv.2007.05.010

Cite this

Buckton, A. J., Kulasegaram, R., Ngui, S. L., Fisher, M., James, R., Rangarajan, S., & Teo, C. G. (2007). Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-α 2b and ribavirin. Journal of Clinical Virology, 40(1), 60-63. https://doi.org/10.1016/j.jcv.2007.05.010

@article{f2676e20f6984dc6b344a4bce5084229,

title = "Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-α 2b and ribavirin",

abstract = "An HIV-1/hepatitis C virus (HCV) co-infected patient with haemophilia received a 48-week course of pegylated interferon-α-2b and ribavirin therapy for genotype 5a HCV infection. Virological response was achieved at week 24. At the end of treatment, HCV RNA in serum was detected and identified to belong to genotype 2b, rather than genotype 5a. A sensitive method for identifying minority HCV genotypes in pre-treatment serum showed genotype 2b HCV carriage prior to treatment. Sequencing the interferon sensitivity-determining region of the HCV NS5A gene obtained from pre-, intra- and post-treatment sera revealed emergence of quasispecies bearing R → K and M → A/T mutations at codons 2222 and 2223, respectively. Occult presence of minority HCV subpopulations and their acquisition of mutations following therapy can result in poor treatment outcome.",

keywords = "Genotype switch, Haemophilia, Multitypic HCV infection",

author = "Buckton, {A. J.} and R. Kulasegaram and Ngui, {S. L.} and M. Fisher and R. James and S. Rangarajan and Teo, {C. G.}",

note = "Funding Information: The laboratory studies were funded by a grant from the Department of Health, England.",

year = "2007",

month = sep,

doi = "10.1016/j.jcv.2007.05.010",

language = "English",

volume = "40",

pages = "60--63",

journal = "Journal of Clinical Virology",

issn = "1386-6532",

publisher = "Elsevier",

number = "1",

}

Buckton, AJ, Kulasegaram, R, Ngui, SL, Fisher, M, James, R, Rangarajan, S & Teo, CG 2007, 'Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-α 2b and ribavirin', Journal of Clinical Virology, vol. 40, no. 1, pp. 60-63. https://doi.org/10.1016/j.jcv.2007.05.010

Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-α 2b and ribavirin. / Buckton, A. J.; Kulasegaram, R.; Ngui, S. L. et al.
In: Journal of Clinical Virology, Vol. 40, No. 1, 09.2007, p. 60-63.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-α 2b and ribavirin

AU - Buckton, A. J.

AU - Kulasegaram, R.

AU - Ngui, S. L.

AU - Fisher, M.

AU - James, R.

AU - Rangarajan, S.

AU - Teo, C. G.

N1 - Funding Information: The laboratory studies were funded by a grant from the Department of Health, England.

PY - 2007/9

Y1 - 2007/9

N2 - An HIV-1/hepatitis C virus (HCV) co-infected patient with haemophilia received a 48-week course of pegylated interferon-α-2b and ribavirin therapy for genotype 5a HCV infection. Virological response was achieved at week 24. At the end of treatment, HCV RNA in serum was detected and identified to belong to genotype 2b, rather than genotype 5a. A sensitive method for identifying minority HCV genotypes in pre-treatment serum showed genotype 2b HCV carriage prior to treatment. Sequencing the interferon sensitivity-determining region of the HCV NS5A gene obtained from pre-, intra- and post-treatment sera revealed emergence of quasispecies bearing R → K and M → A/T mutations at codons 2222 and 2223, respectively. Occult presence of minority HCV subpopulations and their acquisition of mutations following therapy can result in poor treatment outcome.

AB - An HIV-1/hepatitis C virus (HCV) co-infected patient with haemophilia received a 48-week course of pegylated interferon-α-2b and ribavirin therapy for genotype 5a HCV infection. Virological response was achieved at week 24. At the end of treatment, HCV RNA in serum was detected and identified to belong to genotype 2b, rather than genotype 5a. A sensitive method for identifying minority HCV genotypes in pre-treatment serum showed genotype 2b HCV carriage prior to treatment. Sequencing the interferon sensitivity-determining region of the HCV NS5A gene obtained from pre-, intra- and post-treatment sera revealed emergence of quasispecies bearing R → K and M → A/T mutations at codons 2222 and 2223, respectively. Occult presence of minority HCV subpopulations and their acquisition of mutations following therapy can result in poor treatment outcome.

KW - Genotype switch

KW - Haemophilia

KW - Multitypic HCV infection

UR - http://www.scopus.com/inward/record.url?scp=34548119852&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2007.05.010

DO - 10.1016/j.jcv.2007.05.010

M3 - Article

C2 - 17631045

AN - SCOPUS:34548119852

SN - 1386-6532

VL - 40

SP - 60

EP - 63

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

IS - 1

ER -

Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-α 2b and ribavirin

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this